The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 11, 2014

Filed:

Dec. 02, 2011
Applicants:

William Washburn, Titusville, NJ (US);

Jean Whaley, Beminster, NJ (US);

Mario Maidonado, Basel, CH;

James F. List, Princeton, NJ (US);

Frederick T. Fiedorek, Princeton, NJ (US);

Inventors:

William Washburn, Titusville, NJ (US);

Jean Whaley, Beminster, NJ (US);

Mario Maidonado, Basel, CH;

James F. List, Princeton, NJ (US);

Frederick T. Fiedorek, Princeton, NJ (US);

Assignee:

AstraZeneca AB, Sodertalje, SE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/70 (2006.01); A61K 31/00 (2006.01); A61K 31/7034 (2006.01); A61K 45/06 (2006.01); A61K 31/7004 (2006.01);
U.S. Cl.
CPC ...
A61K 31/00 (2013.01); A61K 31/7004 (2013.01); A61K 31/70 (2013.01); A61K 31/7034 (2013.01); A61K 45/06 (2013.01);
Abstract

Methods are provided for treating obesity or causing weight loss in a mammalian subject or patient, wherein a therapeutically effective amount of an SGLT2 inhibitor alone or optionally in combination with another anti-obesity agent, is administered to a mammalian subject or patient. In addition, a pharmaceutical composition is provided which comprises an SGLT2 inhibitor, alone or in combination with another anti-obesity agent, and a pharmaceutically acceptable carrier thereof.


Find Patent Forward Citations

Loading…